Vanguard Group Inc. Trims Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Vanguard Group Inc. lowered its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIOFree Report) by 3.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,275,981 shares of the company’s stock after selling 409,016 shares during the quarter. Vanguard Group Inc. owned about 0.06% of BridgeBio Pharma worth $297,348,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC acquired a new stake in shares of BridgeBio Pharma during the 3rd quarter worth approximately $403,000. Moody Aldrich Partners LLC boosted its stake in shares of BridgeBio Pharma by 72.2% during the 3rd quarter. Moody Aldrich Partners LLC now owns 137,512 shares of the company’s stock worth $3,626,000 after acquiring an additional 57,639 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of BridgeBio Pharma by 170.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 665,604 shares of the company’s stock worth $17,552,000 after acquiring an additional 419,813 shares in the last quarter. Primecap Management Co. CA boosted its stake in shares of BridgeBio Pharma by 34.9% during the 3rd quarter. Primecap Management Co. CA now owns 938,700 shares of the company’s stock worth $24,754,000 after acquiring an additional 242,608 shares in the last quarter. Finally, Boone Capital Management LLC bought a new stake in shares of BridgeBio Pharma during the 3rd quarter worth $8,264,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Wells Fargo & Company assumed coverage on BridgeBio Pharma in a report on Friday, December 8th. They issued an “overweight” rating and a $58.00 target price for the company. Citigroup increased their target price on BridgeBio Pharma from $42.00 to $46.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Raymond James assumed coverage on BridgeBio Pharma in a report on Thursday, March 21st. They issued an “outperform” rating and a $45.00 target price for the company. BMO Capital Markets assumed coverage on BridgeBio Pharma in a report on Wednesday, January 31st. They issued a “market perform” rating and a $37.00 target price for the company. Finally, JPMorgan Chase & Co. increased their target price on BridgeBio Pharma from $35.00 to $45.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $45.62.

Read Our Latest Research Report on BBIO

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, Director Hannah Valantine sold 2,915 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $37.97, for a total transaction of $110,682.55. Following the transaction, the director now directly owns 1,764 shares in the company, valued at $66,979.08. The transaction was disclosed in a filing with the SEC, which is available through this link. In other BridgeBio Pharma news, Director Hannah Valantine sold 2,915 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $37.97, for a total transaction of $110,682.55. Following the transaction, the director now directly owns 1,764 shares in the company, valued at $66,979.08. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Randal W. Scott sold 2,500 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $34.00, for a total value of $85,000.00. Following the transaction, the director now owns 6,500 shares in the company, valued at $221,000. The disclosure for this sale can be found here. Corporate insiders own 28.52% of the company’s stock.

BridgeBio Pharma Trading Up 3.7 %

Shares of NASDAQ:BBIO opened at $30.86 on Thursday. BridgeBio Pharma, Inc. has a 1 year low of $12.75 and a 1 year high of $44.32. The business has a fifty day simple moving average of $33.26 and a 200 day simple moving average of $31.75. The firm has a market cap of $5.43 billion, a price-to-earnings ratio of -7.84 and a beta of 1.05.

BridgeBio Pharma (NASDAQ:BBIOGet Free Report) last posted its earnings results on Thursday, February 22nd. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.09). The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $4.78 million. During the same quarter in the prior year, the business posted ($0.92) EPS. BridgeBio Pharma’s quarterly revenue was down 8.4% on a year-over-year basis. On average, sell-side analysts forecast that BridgeBio Pharma, Inc. will post -3.09 EPS for the current year.

BridgeBio Pharma Company Profile

(Free Report)

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

Recommended Stories

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIOFree Report).

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.